p53 expression and HPV DNA as clinical prognostic factors in early cervical carcinoma
Department of Obstetrics and Gynecology, Kansai Medical University, Osaka, Japan
AIM: Cervical cancer have high risk types of HPV DNA which encoded the E6 oncogene. This protein has been shown to inactivate the functions of human oncosuppressor protein p53. However,the correlation between the HPV types and p53 overexpression in patients with cervical cancer is not clear. We assessed whether overexpression of p53 protein or HPV DNA correlate with the recurrence as well as several known prognostic factors in uterine cervical cancer. METHOD: Forty-nine patients with cervical cancer ( FIGO stage IA-IIB ) who underwent hysterectomy were retrospectively studied. All 49 cancer tissue samples were examined for immunohistochemical study using the mouse monoclonal antibody p53 ( clone DO-7 ). Twenty-five of 49 were examined for the detection and typing of HPV DNA by PCR-RFLP method. RESULT: Overexpression of p53 was demonstrated in twenty of 49 ( 40.8% ) patients with cervical cancer. A significant association between p53 overexpression and age, FIGO stage, recurrence or risk of death was observed.However, there was not significant p53 overexpression and lymphnode metastases or parametrium involvement. HPV DNA was detected in nineteen of 25 ( 76% ) patients with cervical cancer. There was no relation between HPV DNA and age, FIGO stage, lymphnode metastases, parametrium involvement, recurrence or risk of death. The correlation between p53 overexpression and HPV types was not statistically significant.A significant association with recurrence and parametrium involvement was observed. Lymphnode metastases correlated with the rate of recurrence. CONCLUSION: p53 overexpression was associated with age, FIGO stage, recurrence or risk of death in uterine cervical carcinoma.
Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Nice, France; February 7 - 10, 2004; in oral session 791 (Viral Infections).